Ovid Therapeutics Q3 2022 net loss $12.0M; $137.9M cash; OV329 Phase 1 to start Q4

Ovid Therapeutics Inc.

2022-Q3 EPS reported -$0.61 revenue$1,456,468

Net loss of $12.0M ($0.17 per share) vs $11.4M loss in Q3 2021; R&D expense $5.2M.
Cash, cash equivalents and marketable securities totaled $137.9M as of Sept 30, 2022.
FDA cleared IND for OV329; Phase 1 trial in healthy volunteers planned for Q4 2022.
Executed additional $3.5M investment in Gensaic convertible preferred stock for gene delivery platform.
Takeda continues pivotal Phase 3 trials for soticlestat; Ovid eligible for up to $660M milestones plus royalties.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Ovid Therapeutics Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022 , Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Third Quarter 2022 Financial Results and Corporate Highlights.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-028771

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.